23-Valent Pneumococcal Polysaccharide Vaccine
It selects 23 serotypes of pneumococci that are the most widely prevalent and invasive. Advanced manufacturing technologies are adopted to improve antigen purity and enhance safety.
This product completed Phase I clinical trials in April 2023. The Phase I clinical trials showed that this product could trigger a strong immunogenic response (in subjects aged 2 years and above), indicating significant vaccine efficacy. The incidence of vaccination-related adverse events (AE) was lower than that in the control group. After the completion of Phase I clinical trials, the process was further improved and optimized through independent research and development. It is planned to initiate Phase III clinical trials in Q4 2025/Q1 2026.
For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.
ONLINE
NEW PRODUCTS
Need more help?
Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.
CONTACT
- E-Mail: yue.peng@yitherbiotech.com
- Hotline: +86-021-61639751
- Address: No. 5, Lane 1690, zhangheng Road, Pudong New Area, Shanghai
SHARE
Copyright: Yither Biotechnology Co. Ltd Powered by:www.30.cn SEO
